Board meeting: Q3 results, new director, EUR 3M Singapore fund infusion

Management Changes View source PDF Explain this filing

TARSONS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.9%Reaction day

₹207.01

prior close

₹203.71

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%+4.7% vs market

Medical Equipment & Supplies peers, median of 9sector+1.1%+2.7% vs sector

On the reaction day the stock moved 4.7 pts more than Nifty Microcap 250 and 2.7 pts more than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+3.6

10m

+3.1

15m

+2.5

30m

+3.7

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.9-0.8+4.7+1.1+2.7

Next day

+3.4+1.8+1.6+1.7+1.7

+5.3+2.8+2.5+2.2+3.1

+0.4+2.3-1.9+1.4-1.0

-3.1+1.8-4.9+4.3-7.4

-3.9+0.3-4.1+1.5-5.4

-2.2+0.5-2.7+1.6-3.8

15d

-7.5-2.5-5.0-0.7-6.8

-8.4-6.3-2.0-7.3-1.1

-10.8-8.0-2.8-6.7-4.1

+10.2+8.3+2.0+2.5+7.7

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 9Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Tarsons Products board on Feb 6, 2026 approved Q3 FY26 standalone results (revenue 839.88M, up 10% YoY; net profit 70.94M vs 76.13M YoY) and 9M results. Infused EUR 3M into wholly-owned Singapore subsidiary for operations. Appointed Mr. Vinesh Mohan Kriplani (ex-EY, KPMG, PwC) as Non-Executive Independent Director for 5 years. Mr. Girish Paman Vanvari resigned as Independent Director citing personal commitments, 3 months before his term expiry. Board committees reconstituted.

Likely market impact

Director reshuffle with new appointee bringing strong tax and M&A expertise. EUR 3M Singapore fund infusion. Q3 profit softened YoY.